The fertility pipeline is moving into four new outsourcing demand pools. This map shows the products in development, the exact CRO / CDMO / diagnostic capabilities each one needs to reach the clinic — and links every manufacturing need to real CDMOs already in our directory.
Most directories list suppliers and stop. This is a demand-side map: we start from what the IVF pipeline is actually trying to build, decompose each product into the capabilities it requires, then bridge that demand straight to supply. Nobody else does demand→supply mapping for reproductive medicine.
Where the fertility market is creating new, outsourceable development work.
Oral non-hormonal drugs and uterine-receptivity products that raise pregnancy and live-birth rates.
Ex vivo egg maturation and cell-based ovarian support — moving biology out of the body and into the lab.
AI embryo selection and IVF lab automation, validated against pregnancy and live-birth outcomes.
Non-invasive PGT-A, cfDNA, embryo culture-media testing, and molecular assay validation.
For each product we show the development profile, then map every required manufacturing capability to a real directory facet with its live CDMO count. Click a capability to see the CDMOs that offer it.
Oxolife · Spain
Non-hormonal oral small molecule for endometrial receptivity
Stage / recent result
Phase II data showed improved pregnancy and live-birth signals; larger Phase III confirmation needed.†
CRO & clinical needs
IVF clinical-trial sites, reproductive-medicine CRO, PK/PD, reproductive toxicology, biostatistics.
CDMO / manufacturing needs — covered in directory
Small molecule API, oral formulation, stability, analytical method validation.
Gameto · USA
iPSC-derived ovarian support-cell technology for ex vivo oocyte maturation
Stage / recent result
FDA-cleared Phase III trial; designed to reduce hormone-injection burden and mature eggs outside the body.†
CRO & clinical needs
Embryology labs, IVF trial networks, reproductive-endocrinology sites, cell-potency assay support.
CDMO / manufacturing needs — covered in directory
iPSC cell banking, GMP cell-therapy manufacturing, cryopreservation, aseptic processing, QC release testing.
Qilu Pharmaceutical · China
Recombinant FSH biosimilar
Stage / recent result
Phase III completed in China; bioequivalence study planned/active for comparison with Gonal-f.†
CRO & clinical needs
Biosimilar comparability, PK/PD, immunogenicity, reproductive-endocrinology trials.
CDMO / manufacturing needs — covered in directory
Mammalian cell culture, recombinant protein purification, sterile injectable fill-finish, cold-chain packaging.
ReproNovo · Netherlands
Oral oxytocin receptor antagonist for embryo implantation / adenomyosis
Stage / recent result
Described as Phase II-ready / entering Phase II development; not clearly Phase III yet.†
CRO & clinical needs
IVF implantation studies, adenomyosis/endometriosis clinical sites, reproductive pharmacology, imaging endpoints.
CDMO / manufacturing needs — covered in directory
Small molecule API, oral dosage formulation, clinical packaging.
IBSA · Switzerland
Hormonal luteal-phase support formulation
Stage / recent result
Listed as Phase III; should be further verified against trial registry before external publication.†
CRO & clinical needs
Bioequivalence, luteal-support trials, reproductive-endocrinology sites.
CDMO / manufacturing needs — covered in directory
Sterile injectable or softgel formulation, fill-finish, stability, packaging.
CooperSurgical / Igenomix · and others
cfDNA-based embryo genetic testing from spent culture media
Stage / recent result
Validation-stage technology; aims to reduce embryo biopsy by using culture-media DNA.†
Diagnostics & clinical needs
NGS assay development, cfDNA extraction, bioinformatics, reference standards, clinical validation.
CDMO / manufacturing needs — expansion area
Oligonucleotide / reagent manufacturing, PCR/NGS kit components, controls, QC materials.
Vitrolife / Harrison.ai, Presagen · and others
AI / computer-vision embryo assessment
Stage / recent result
Clinical-validation focus is shifting from grading accuracy to pregnancy / live-birth outcomes.†
Services & CRO needs
AI model validation, IVF image datasets, medical-software QA, SaMD regulatory, cybersecurity, cloud hosting, multicenter IVF validation studies, data management, real-world evidence.
CDMO / manufacturing needs — expansion area
This is a software/diagnostics product — its supplier needs sit in AI-validation and SaMD regulatory partners, which the directory does not yet cover.
Ranked by how many pipeline products in this map require each manufacturing capability.
Manufacturing capabilities IVF pipelines pull on
Width = number of mapped products; figure = live CDMOs in the directory.
The implantation-drug wave (OXO-001, Nolasiban) leans on the directory's deepest pools — 418 small-molecule API and 321 oral-solid-dose CDMOs. Supply here is abundant.
The hormone and luteal-support products (QL1012, Progesterone-IBSA) converge on sterile fill/finish (274) — a well-covered but quality-sensitive bottleneck.
The lab-biology frontier (Fertilo) needs cell-therapy GMP capacity, where supply is thinnest (93–94 CDMOs) — the highest-value matchmaking opportunity.
The manufacturing side of this pipeline maps cleanly to the directory today. The clinical, diagnostic, and digital sides do not — yet. That is roadmap, not weakness.
IVF clinical-trial sites, reproductive-endocrinology networks, embryology labs, PK/PD and reproductive-tox partners. Every drug product above needs them; none are in the directory yet.
NGS assay development, cfDNA extraction, oligonucleotide/reagent manufacturing, PCR/NGS kit components and QC controls — the supply base behind non-invasive PGT-A.
AI model validation, IVF image datasets, medical-software QA, SaMD regulatory, cybersecurity and cloud hosting — the service layer behind AI embryo selection.
Regulatory affairs and registry specialists focused on fertility products and reproductive endpoints, to round out a full demand→supply map for the modality.
† Accuracy disclaimer. Clinical stages and recent results shown above are drawn from public sources and an internal pipeline document. All clinical stages are pending trial-registry verification before any external publication. Directory figures reflect CDMO Hub directory data as of the most recent enrichment pass (2,358 CDMOs; ~1,626 enriched profiles; 3,652 facilities). There is no "reproductive medicine" therapeutic-area facet in the directory yet — this map links by capability, not by therapeutic area.
Browse the manufacturing capabilities your pipeline needs, or use the AI Matchmaker to find qualified CDMO partners from the directory. Free for buyers.